



Published in final edited form as:

*Nat Rev Immunol.* 2019 June ; 19(6): 369–382. doi:10.1038/s41577-019-0127-6.

## Macrophages as regulators of tumor immunity and immunotherapy

David G. DeNardo<sup>1,\*</sup>, Brian Ruffell<sup>2,\*</sup>

<sup>1</sup>Department of Medicine, ICCE Institute, Department of Pathology and Immunology, Siteman Cancer Center, Washington University in St. Louis, School of Medicine, St. Louis, MO 63110, USA

<sup>2</sup>Department of Immunology; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA

### Abstract

Macrophages are critical mediators of tissue homeostasis, with tumors distorting this proclivity to stimulate proliferation, angiogenesis, and metastasis. This had led to an interest in targeting macrophages in cancer, and preclinical studies have demonstrated efficacy across therapeutic modalities and tumor types. Much of the observed efficacy can be traced to the suppressive capacity of macrophages, driven by microenvironmental cues such as hypoxia and fibrosis. As a result, tumor macrophages display an ability to suppress T cell recruitment and function as well as regulate other aspects of tumor immunity. With the increasing impact of cancer immunotherapy, macrophage targeting is now being evaluated in this context. Here we will discuss the results of clinical trials and the future of combinatorial immunotherapy.

### Keywords

tumor-associated macrophages; immunotherapy; checkpoint blockade; chemotherapy; tumor microenvironment

### Introduction

The presence of tumor-associated macrophages (TAMs) is generally associated with a poor prognosis in solid tumors. This has been shown in studies performed on individual tumor types using traditional immunohistochemistry techniques to quantify cellular density<sup>1,2</sup> and in more recent analyses that infer the presence of macrophages across malignancies using gene expression profiles<sup>3</sup>. These findings are consistent with the established role of macrophages in promoting multiple aspects of tumorigenesis in experimental models, from initiation through to angiogenesis and systemic dissemination<sup>4,5</sup>. Most relevant for patients, TAMs are known to suppress responses to standard-of-care therapeutics, including chemotherapy, irradiation, and angiogenic inhibitors<sup>6–9</sup>. Although this includes direct regulation of survival and cell death pathways in tumor cells<sup>10,11</sup>, *in vivo* modeling indicates

\*Correspondence: ddenardo@wustl.edu, brian.ruffell@moffitt.org.

that improved efficacy following macrophage depletion is often dependent upon enhanced recruitment or function of cytotoxic CD8<sup>+</sup> T cells<sup>6</sup>. Perhaps not surprisingly, macrophage antagonists demonstrate combinatorial efficacy when combined with immunotherapy, including checkpoint blockade<sup>12</sup>. Clinical trials examining these combinations are now ongoing. In this Review, we will discuss how macrophages are induced into becoming immunosuppressive, the mechanisms by which they suppress anti-tumor immunity, and how this information is being utilized to develop therapeutics and design clinical trials.

## Factors Regulating Macrophage Function

Macrophages are not a single cell population with a defined phenotype and biological activity, but rather a diverse collection of cell types with a wide range of functional roles in homeostatic and pathological conditions. This diversity of cellular activities is regulated by input from three distinct elements: developmental origin, tissue of residence, and acute microenvironmental cues (Figure 1). The diversity of macrophage functions is regulated in turn by the integration of the epigenetic memory of these cells and their plasticity to respond to new cues<sup>13–16</sup>. The extent to which macrophages regulate tumor growth is therefore critically linked to properties of the tumor itself. This includes a role for malignant cell-derived factors such as CSF1 and CCL2 in promoting macrophage recruitment; however, the elements within the tumor microenvironment (TME) and tumor immune microenvironment (TIME), such as fibrosis, hypoxia, nutrient availability, and lymphocyte-derived factors, appear to most dramatically shift macrophage phenotypes (Figure 2). Prior to discussing these factors, it is important to note that most of the available data are contextualized within the binary M1/M2 polarization system. Thus, macrophages have traditionally been considered anti-tumorigenic when they express high levels of tumor necrosis factor (TNF), inducible nitric oxide synthase (iNOS) or MHC class II molecules, and pro-tumorigenic when they express high levels of arginase-1 (ARG1), IL-10, CD163, CD204, or CD206<sup>17</sup>. Changes to any of these markers were then used to conclude that macrophage repolarization has occurred. However, it is now clear that macrophage activation states consist of a continuum of phenotypes, and the use of markers to delineate their functional role within the tumor is circumspect<sup>18</sup>. In the following sections we will therefore highlight studies that demonstrate a change in macrophage phenotype and function *in vivo*. Although not discussed here, it should also be acknowledged that factors such as anatomical location, pathological or molecular cancer subtype, and even the specific microenvironmental niche occupied by the cell likely contribute to inter- and intra-tumoral macrophage heterogeneity (Box 1). Thus the role of macrophages in cancer types can differ considerably<sup>6</sup>, and there may even be an underappreciated level of variability between individual patients.

### Macrophage origin.

Macrophages arise from three distinct developmental pathways (Figure 1). A large proportion of tissue-resident macrophages are now recognized as originating from embryonic precursors that seed tissues in the prenatal and perinatal periods. This occurs in at least two functional waves, with macrophage precursor cells from fetal yolk sac or fetal liver progenitors<sup>16,19</sup>. These precursors seed distant tissue and give rise to locally proliferating, self-maintained tissue-resident macrophages that can persist into adulthood<sup>16,19–22</sup>. For

some tissues, such as the colon, these embryonic macrophages are rapidly replaced by monocytes derived from hematopoietic stem cells (HSCs) after birth. However, for other macrophage subsets, such as microglia, their sole origin appears to be embryonic, with little contribution from HSCs under homeostatic conditions<sup>23,24</sup>. Still other tissues contain macrophages with a mixed origin, including the pancreas, breast, and lung<sup>25–28</sup>. The relevance of this remains to be determined, though it is known that tissue macrophages of both embryonic and HSC origin assume epigenetically-regulated programs indicative of their residence in these tissues (e.g., brain, liver, and lung) to drive specific phenotypes, especially those related to metabolism and interferon responsiveness<sup>28–30</sup>.

In tumors, however, several recent studies have suggested that embryonic-derived macrophages may have distinct phenotypes and functions compared to their monocyte-derived counterparts<sup>28,31,32</sup>. TAMs are usually thought to predominantly derive from circulating monocytes<sup>33,34</sup>, but up to 50% of the macrophages in murine models of brain, lung and pancreatic cancer were found to derive from tissue-resident populations<sup>28,31,32</sup>. Within these tumors the TAMs of HSC origin have elevated expression of genes involved in immunosuppressive networks and antigen presentation<sup>31,32,35</sup>. In contrast, embryonic-derived TAM gene sets are enriched for tissue remodeling and wound healing. These data suggest that tissue and origin-specific programs can fine tune macrophage responses in ways that may have significant impact on tumor immunity; however, the rules for how these programs might integrate with macrophage polarizing cues are largely unknown. Additionally, while the origins of macrophages have been mapped in multiple animal models, our ability to interrogate these populations in human tissues is limited. Thus, one challenge for the field going forward will be to determine the impact of these findings in human cancers, perhaps with an approach such as single cell RNA-sequencing to permit an evaluation of macrophage heterogeneity and origin.

### Metabolism.

Tissue hypoxia impacts macrophages in two ways. First, hypoxia can induce the production of key monocyte recruitment factors including CCL2, CCL5, CXCL12, CSF-1, and VEGF by tumor cells and the stroma. Once recruited into hypoxic regions, the receptors for several of these factors are downregulated, effectively locking TAMs in hypoxic microenvironments<sup>36</sup>. Second, macrophages directly sense hypoxic conditions via hypoxia-inducible factors (HIFs): the absence of HIF-1 $\alpha$  leads to reduced arginase-1 expression and immunosuppressive activity *in vitro*<sup>37</sup>, and the absence of HIF-2 $\alpha$  reduces macrophage infiltration and cytokine production<sup>38</sup>. In both cases, myeloid-specific loss of these factors significantly delays tumor progression in autochthonous tumor models<sup>37,38</sup>. Notably, the localization of TAMs in hypoxic regions is critical to the generation of an immunosuppressive phenotype *in vivo*, because myeloid-specific loss of neuropilin-1, which excludes macrophages from hypoxic areas, promotes anti-tumor immunity<sup>39</sup>. However, it should be noted that the roles of neuropilin-1 and its ligand, SEMA3A, remain controversial<sup>40</sup>, and that HIF-1 $\alpha$  can also be stabilized by the presence of lactic acid<sup>41</sup>.

Irrespective of tissue hypoxia, aerobic glycolysis within tumors can limit glucose availability and promote the accumulation of organic acids. Do these factors also impact macrophage

function? Macrophages stimulated with lipopolysaccharide (LPS) and/or IFN $\gamma$  display enhanced glucose uptake and aerobic glycolysis<sup>42</sup>, and consistent with the important role for this metabolic shift, increasing glucose transport promotes expression of reactive oxygen species<sup>43</sup>. This is in contrast to IL-4-stimulated macrophages, which show preferential oxidative phosphorylation and fatty acid oxidation<sup>42</sup>, and are therefore not impacted by impaired glycolysis<sup>44</sup>. Presumably low glucose availability will thus favor TAMs to adopt a pro-tumor polarization state, but this has not been formally demonstrated. However, because a metabolic shift does control macrophage function, interfering with the genetic regulators of this process can blunt the pro-tumor bioactivity of TAMs and reduce tumor growth in animal models<sup>45–47</sup>.

As mentioned above, lactic acid promotes *Vegf* and *Arg1* expression by macrophages in a *Hif1a*-dependent manner<sup>41</sup>. This is not true for lactate salt<sup>41</sup>, indicative of a role for acidic pH in either promoting the activity of monocarboxylate transporters<sup>48</sup> and/or acidic pH directly regulating macrophage polarization. In support of the second scenario, a recent study found that a pH of 6.1 was sufficient to promote expression of *Arg1*, *Vegfa*, and *Hif1a* by unstimulated macrophages *in vitro*<sup>49</sup>, and similar observations have been made at pH 6.8 during stimulation with IL-4<sup>50</sup>. Increasing the pH within tumors similarly reduces expression of *Arg1* by TAMs<sup>50</sup>. How macrophages sense pH at a molecular level is somewhat vague, but activation appears to be mediated by G protein-coupled receptors and production of cAMP<sup>51</sup> leading to expression of the transcription factor ICER (inducible cyclic AMP early repressor)<sup>49</sup>. Importantly, mice with myeloid-specific deficiency of ICER resist the growth of highly glycolytic tumors<sup>49</sup>.

### Fibrosis.

Desmoplasia is a hallmark of many solid tumors, with pancreatic cancer representing one extreme end of the spectrum. Fibrotic stroma has the potential to shape the TAM phenotype through direct effects of its components, like activated fibroblasts, changes in the extracellular matrix (ECM), or indirect effects on factors such as oxygen and nutrient availability. Cancer-associated fibroblasts (CAFs) are perhaps the most relevant component of fibrosis because these cells overexpress numerous pro-inflammatory cytokines (e.g., CCL2, CCL3, CCL5, IL-6, GM-CSF, CSF-1, VEGF, and CXCL8) with the potential to regulate recruitment, differentiation, and activation of TAMs<sup>52–56</sup>. In particular, CAFs have been reported to impair the maturation of macrophages, locking recruited monocytes in an immature, suppressive state. This is possibly due to high levels of IL-6 production, especially in pancreatic CAFs, which can induce STAT3 phosphorylation and prevent macrophage differentiation<sup>57–59</sup>. In addition, IL-6 production by endothelial cells has been shown to promote M2-like polarization and tumor growth in a glioblastoma model<sup>60</sup>, and TAMs themselves produce IL-6 in multiple other model systems<sup>33,61,62</sup>. The source of these polarizing cytokines may therefore vary considerably across tumor types or even within microenvironments of the tumor. Adding to this complexity is the diversity of CAF subsets and their differential potential to alter immune function<sup>63,64</sup>. Thus, although CAFs are assumed to be important regulators of TAM function, their role remains poorly defined *in vivo*.

The extensive ECM associated with fibrosis can also impact macrophages in several ways. Periostin has been shown to promote TAM recruitment via integrin binding<sup>65</sup>, while collagen promotes an M2-like phenotype<sup>66–68</sup>, with the increased presence of collagen I acting as a reservoir for secreted factors, such as transforming growth factor  $\beta$  (TGF $\beta$ ), or directly activating inhibitory receptors such as leukocyte-associated immunoglobulin-like receptor 1 (LAIR1)<sup>69</sup>. In addition to the concentration of ECM components, their macromolecular structure, including biophysical and mechanical properties, can direct macrophage function within tumors. Collagen crosslinking and matrix stiffness are properties of solid tumors that have direct effects on macrophage differentiation, motility, and phenotype<sup>70–72</sup>. This is largely mediated by  $\beta$ 1 integrin clustering and hyperactivation of focal adhesion kinases (FAK), and genetic or pharmacological loss of FAK signaling reduces tumor fibrosis<sup>73</sup> and the number of M2-like TAMs<sup>74,75</sup>, leading to improved anti-tumor immunity and response to immune checkpoint blockade<sup>74</sup>.

Other ECM components known to regulate macrophage activation include hyaluronan, versican, and tenascin, mostly through altered forms of these molecules being recognized as damage-associated molecular patterns (DAMPs) by Toll-like receptor 2 (TLR2) or TLR4<sup>76</sup>. Versican acts via TLR2 to increase expression of receptors for IL-6 and IL-10 and sensitizes cells to these cytokines<sup>77</sup>. In tumor models, versican has been suggested to promote metastasis via macrophage activation<sup>78</sup>. Meanwhile, hyaluronan production by fibroblasts or keratinocytes promotes macrophage recruitment<sup>79,80</sup>, possibly through its role in providing a scaffold for ECM proteoglycans and enhancing chemokine retention. Hyaluronan has also been shown to alter macrophage activation *in vitro* through CD44 or TLR2/TLR4, depending on the state of the cells and the molecular weight of the hyaluronan<sup>81</sup>.

### Cellular debris.

Cell death is prevalent within tumors, particularly regions of hypoxia, and is significantly induced by anti-cancer therapies. Whereas the release of intracellular DAMPs can promote tumor immunity through activation of dendritic cells (DCs)<sup>82</sup>, the chronic stimulation of macrophages induces negative regulatory mechanisms to dampen inflammation. Thus, although the release of HMGB1 in response to chemotherapy promotes immunity via TLR4, it can also drive IL-10 expression in TAMs via the receptor for advanced glycation end products<sup>83</sup>. Whether this is true for other DAMPs in tumors is unknown, but even the expression of pro-inflammatory cytokines such as IL-1 $\beta$ , IL-6, and TNF by macrophages can promote tumor progression<sup>6</sup>. Macrophage recognition of apoptotic cells is also well-known to suppress their activation potential<sup>84</sup>, with activation of the MerTK receptor elevating expression of immunosuppressive factors such as TGF $\beta$ , IL-10, and arginase-1<sup>85,86</sup>. Consistent with this observation, loss of MerTK in the stromal compartment leads to macrophage repolarization and T cell-dependent growth restraint<sup>86</sup>, as well as a prolonged response to radiation therapy<sup>87</sup>. Similarly, the deletion of protein S in tumor cells, which mediates the recognition of phosphatidylserine-presenting membranes by MerTK/Tyro3, increases iNOS expression and leukocyte infiltration<sup>88</sup>. It remains possible that activation of select pattern recognition receptors may shift macrophages towards an anti-tumor phenotype, especially when using agonists therapeutically. However, it generally

appears that recognition of cellular and extracellular debris by macrophages is detrimental in terms of tumor growth.

### Lymphocytes.

Most lymphocyte subpopulations can be identified within the tumor stroma, with the composition and density varying by tissue, molecular subtype, and individual patient. In addition to directly impacting tumor growth, many of these populations have been shown to shape the phenotype of macrophages in some fashion<sup>89</sup> (Figure 2). IFN $\gamma$  can be produced by CD8<sup>+</sup> CTLs, T helper 1 (T<sub>H</sub>1) cells and natural killer (NK) cells and primes macrophages towards a classically-activated phenotype, increasing macrophage antigen presentation and pro-inflammatory cytokine production, and direct tumor cell killing<sup>90</sup>. Similarly, expression of CD40 ligand (CD40L) by T cells can activate monocytes via CD40 to increase their expression of MHC class II, iNOS, and TNF. This induction of an anti-tumor phenotype is needed during acute T cell responses following therapeutic intervention<sup>91,92</sup>, and could presumably promote a cycle of anti-tumor immunity if maintained.

Unfortunately, many lymphocyte-derived factors engage the tumor-promoting activities of TAMs. This includes production of IL-4 and IL-13 by T<sub>H</sub>2-polarized CD4<sup>+</sup> T cells, which enhance epidermal growth factor expression by TAMs to foster cancer cell metastasis<sup>93</sup>, as well as the suppressive activity of TAMs to blunt CD8<sup>+</sup> T cell responses to chemo- and radiation therapy<sup>94</sup>. It also includes a role of FOXP3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells in driving TAMs towards an immunosuppressive phenotype marked by production of IL-10 and expression of B7-H4<sup>95,96</sup>. Although the available data suggest that neutrophils are the major effector cells associated with IL-17-driven responses<sup>97</sup>, IL-17 produced by T<sub>H</sub>17 or  $\gamma\delta$  T cells can increase monocyte recruitment and macrophage activation, and this could possibly lead to immune tolerance when macrophages engulf recruited neutrophils undergoing apoptosis in the tissue<sup>98–100</sup>. Finally, the loss of B cells in murine models inhibits tumor progression, and in squamous cell carcinoma this has been traced to the pathogenic production of autoantibodies, which act via Fc $\gamma$  receptor signaling to promote macrophage-dependent angiogenesis and tumor progression<sup>101,102</sup>. A similar phenotype has been observed in pancreatic tumors, and in both cases, B cell depletion or inhibition of Fc $\gamma$  receptor signaling (Btk, Syk, and PI3K $\gamma$ ) relieves macrophage-mediated T cell dysfunction, leading to delayed progression or improved responses to chemotherapy and PD1 blockade<sup>103–106</sup>.

### Regulation of T cell function by TAMs

Macrophages are widely acknowledged as one of the central suppressive populations within tumors and depleting these cells can unleash T cell responses under several therapeutic conditions<sup>6–8</sup>. Underlying this functional role are molecular mechanisms that range from nutrient depletion to recruitment of T<sub>reg</sub> cells, although the extent to which these mechanisms are involved in any particular tumor is less well defined. Here we will describe what is known about the ability of macrophages to directly or indirectly suppress T cells responses within tumors, as well as discuss several theoretical concepts that may be applicable to cancer (Figure 3).

## Direct regulation of T cells by TAMs.

Numerous studies have shown that TAMs suppress naïve T cell proliferation *ex vivo*, indicating that macrophages can directly suppress T cell function<sup>33,37,107–109</sup>. This is often thought to relate to the ability of murine tumor macrophages to metabolize L-arginine via expression of arginase-1<sup>110</sup>, a common marker of M2-like polarization in murine macrophages, and L-arginine is necessary for T cell fitness and anti-tumor activity<sup>111</sup>. However, neither arginase-1 inhibition nor *Arg-1* deficiency impact macrophage suppressive capacity *in vitro*<sup>109,112</sup>. Instead a secondary role for arginase-1 is only observed when inducible nitric oxide synthase (iNOS/NOS2) is inhibited or absent<sup>33,109,112</sup>. These observations may be a byproduct of the supraphysiological concentration of L-arginine in cell culture medium, because tumor macrophages can deplete L-arginine and prevent recovery of CD3ε expression by T cells following stimulation<sup>113</sup>. Inhibition of arginase-1 *in vivo* also reduces the growth of tumors only in immune competent mice<sup>113</sup>, and *Arg1*-deficiency in macrophages improves responses to adoptive cell transfer therapy (ACT)<sup>112</sup>. However, it remains unclear if these *in vivo* observations are the result of direct immune suppression, the effects of polyamines on tumor cell proliferation<sup>114</sup>, or enhanced production of NO<sup>112</sup>.

The importance of iNOS expression by tumor macrophages is less opaque, at least *ex vivo*<sup>33,109,112</sup>. *Nos2*-deficient tumor myeloid cells lose significant suppressive capacity in co-culture assays<sup>112</sup> and iNOS inhibition restores T cell proliferation in the presence of macrophages<sup>33</sup>. In addition to potential direct effects of NO on T cells<sup>115</sup>, this may be due to secondary production of peroxynitrites, which can prevent the interaction of the T cell receptor with MHC through nitration of either protein<sup>116–118</sup>. *In vivo*, scavenging peroxynitrites with uric acid improves T cell activation and enhances responses to a tumor vaccine<sup>118</sup>, although whether this is attributed to expression by macrophages, other myeloid subsets, or the combination may vary by the tumor model. Based on these observations, it is surprising that iNOS expression by myeloid cells has also been implicated in promoting a T cell response<sup>92,112</sup>. *Nos2*-deficiency diminishes the efficacy of ACT<sup>112</sup>, and at least in the context of low-dose irradiation, this is due to iNOS-expressing macrophages inducing vascular cell adhesion protein (VCAM)-1 expression by the tumor endothelium, leading to enhanced recruitment of adoptively-transferred CD8<sup>+</sup> T cells<sup>92</sup>. Thus, the impact of iNOS expression by macrophages may be highly context dependent, promoting or hindering T cell responses under different therapeutic conditions.

Despite the results in murine models, L-arginine metabolism by macrophages has not been implicated in regulating T cell responses in humans; arginase-1 is expressed by human granulocytes instead of macrophages<sup>95,119,120</sup>, and even combining arginase-1 and iNOS inhibitors fails to blunt macrophage suppressive activity<sup>95</sup>. Instead, the available data points to expression of immune checkpoint ligands as being necessary for suppression. Programmed cell death ligand 1 (PD-L1) expression by CD14<sup>+</sup> or CD68<sup>+</sup> macrophages is observed in multiple cancer tissues, including hepatocellular carcinoma, melanoma, and ovarian cancer<sup>121,122</sup>, and positive correlations have been noted specifically between PD-L1 expression by macrophages and response to programmed cell death 1 (PD-1) blockade<sup>121</sup>. Induced expression of PD-L1 on monocytes also suppresses activation of tumor-specific T

cells *in vitro*, and *in vivo* following adoptive transfer<sup>122</sup>. Similarly, PD-L1 blockade depends upon target expression by CD11b<sup>+</sup> myeloid cells in murine models<sup>121,123</sup>. However, it should be noted that PD-L1 expression by macrophages has not been established as an independent predictor of response, and the relative contribution of PD-L1 expression by tumor cells or the various stromal populations is likely to be highly variable between patients.

The other immune checkpoint ligand that has been identified as functionally important in human macrophages is B7-H4 (also known as B7S1). Although the receptor for B7-H4 is unknown, B7-H4 expressing cells and B7-H4-Ig fusion proteins suppress IL-2 production and T cell proliferation<sup>124</sup>. The fusion protein has also been used to identify expression of the “receptor” in T lymphocytes within healthy livers and hepatocellular carcinomas<sup>125</sup>. Importantly, B7-H4 is preferentially expressed by CD14<sup>+</sup> macrophages within ovarian and liver tumors, and inducing B7-H4 expression on human monocytes/macrophages confers suppressive capacity *in vitro*<sup>95,125</sup>. Blocking B7-H4 also suppresses the growth of subcutaneously implanted tumors in mice by reducing CD8<sup>+</sup> T cell exhaustion<sup>125</sup>; however, other groups have found that B7-H4 promotes or has no impact on tumor immunity in murine models of breast and prostate cancer, respectively<sup>126,127</sup>. These differences may relate to the specifics of the tumor model examined, especially as B7-H4 expression is regulated by cytokines common in the tumor microenvironment such as IL-6, IL-10, and IFN- $\gamma$ <sup>95,127</sup>.

Several other molecules expressed by macrophages potentially have direct suppressive effects on tumor-infiltrating T cells. For example, tumor macrophages can be an important source of IL-10<sup>108</sup>, and IL-10 is known to suppress CD8<sup>+</sup> T cell stimulation by increasing N-glycan branching, thereby reducing co-localization of CD8 protein with the T cell receptor<sup>128</sup>. This process requires the presence of galectin-3, and interfering with this association restores IFN- $\gamma$  expression by CD8<sup>+</sup> T cells from human ovarian ascites<sup>129</sup>. As macrophages can be an important source of galectin-3 in inflamed tissues<sup>130</sup>, tumor macrophages may even regulate both aspects of this suppressive pathway. Macrophages actually express a variety of C-type and I-type lectins, which could represent an additional layer of regulation via protein-carbohydrate interactions. This has not been extensively evaluated, but it is worth noting that the mannose receptor, CD206, which is highly expressed by tumor macrophages, can impair the cytotoxicity of CD8<sup>+</sup> T cells by suppressing CD45 phosphatase activity<sup>131</sup>. Given the importance of carbohydrate modifications in T cell signaling, lectin expression by macrophages may have an unappreciated role in controlling anti-tumor immunity.

### Indirect regulation of T cells by TAMs.

Extending from their function in maintaining tissue homeostasis, macrophages are important regulators of multiple aspects of the tumor microenvironment, in particular the structure of the vasculature and extracellular matrix<sup>6</sup>. Do tumor macrophages regulate T cell recruitment? Several studies have reported that inhibiting macrophage recruitment by targeting the CSF1–CSF1R pathway improves T cell infiltration, including during chemotherapy or high-dose irradiation<sup>12,61,94,107,108</sup>. Similar results are observed when



blocking macrophage recruitment through CCR2 inhibition<sup>61</sup>. Assuming the increase in T cell numbers is not due to changes in cell death or proliferation, the mechanism(s) underlying these observations is unclear.

One possibility could be through regulation of vascular adhesion molecules, but iNOS-expressing macrophages actually promote VCAM1 expression during low-dose irradiation<sup>92</sup>, and while perivascular macrophages regulate vascular structure through expression of VEGFA<sup>132–134</sup>, this would be expected to enhance vessel leakiness and expression of adhesion molecules. Another possible mechanism by which macrophages could suppress T cell recruitment is through production of peroxynitrites and the subsequent nitration of CCL2 or CCL5<sup>135,136</sup>. Nitration of CCL2 specifically has been shown to reduce accumulation of T cells within subcutaneous tumors<sup>137</sup>. This appears to be due to low CCL2-responsiveness by T cells, resulting in nitration preventing chemotaxis of human and mouse T cells without impacting monocyte migration<sup>137</sup>. Although this does not explain the increased T cell recruitment following CCR2 inhibition<sup>61</sup>, it is possible that nitration of CCL5 has a similar effect, especially given its more important role in promoting T cell recruitment into tumours<sup>138</sup>.

Rather than recruitment, it may be that macrophages are involved in restricting the intratumoral localization of T cells. For example, inhibiting reactive nitrogen species can increase the number of CD8<sup>+</sup> T cells within tumors without impacting their frequency in the surrounding stroma<sup>137</sup>. Increasing the degree of fibrosis would be another mechanism by which macrophages could shield tumors from T cell infiltration. This has been shown in pancreatic cancer with macrophage production of granulin promoting the accumulation of myofibroblasts<sup>139,140</sup>. Two recent studies have also reported that TGF $\beta$  signaling acts to exclude T cells from human and murine tumors<sup>141,142</sup>. Tumor macrophages are one of many cells known to produce TGF $\beta$ 1<sup>33,108</sup>, and are not a major source of TGF $\beta$ 2 or TGF $\beta$ 3<sup>141</sup>; however, it is possible that macrophages can regulate desmoplasia through expression of matrix metalloproteinases and activation of latent TGF $\beta$ <sup>143</sup>. Human monocytes and macrophages even display an enhanced ability to activate TGF $\beta$  through their expression of integrin  $\alpha$ v $\beta$ 8<sup>144</sup>. Alternatively, because tumor macrophages are chemotactic for CD8<sup>+</sup> T cells *ex vivo*<sup>103</sup> and have been described to highly express the T cell attracting chemokine *Cxcl10*<sup>33,145,146</sup>, it is conceivable that they could retain T cells within the stroma or perivascular regions of the tumor. Macrophages and T cells are predominantly found within these regions, and at least one study has shown that CSF1R inhibition increases T cell motility and localization in tumor islets<sup>147</sup>.

Macrophages have also been shown to promote T<sub>reg</sub> cell recruitment to human ovarian carcinomas via CCL22 production<sup>148</sup>. In addition to, presumably, suppressing cytotoxic T cell responses, T<sub>reg</sub> cells from ovarian ascites stimulate IL-6 and IL-10 expression by macrophages and increase B7-H4 expression in an autocrine fashion *in vitro*<sup>95,96</sup>. This ability of macrophages to suppress T cell responses via regulation of intermediate cell types has also been described in mammary carcinoma models. In this case, macrophage production of IL-10 suppresses IL-12 expression by CD103<sup>+</sup> conventional dendritic tumor cells (cDC), resulting in a diminished CD8<sup>+</sup> T cell response during chemotherapy<sup>108</sup>. Together, these data highlight macrophages as central drivers of the immunosuppressive

tumor microenvironment through their ability to regulate the recruitment and the function of multiple immune subtypes.

### Phagocytosis and antigen presentation.

Consistent with their name, several studies have confirmed macrophages are the main phagocytic population within tumors<sup>145,146,149</sup>. However, tumor macrophages do not express CCR7 and are unable to migrate into the draining lymph nodes<sup>149,150</sup>. They also display relatively limited ability to activate or restimulate CD8<sup>+</sup> T cells<sup>146</sup>. What impact could phagocytosis by macrophages have on the induction of anti-tumor immunity? First, it is possible that macrophages redirect antigens away from cDCs, an observation that might not be apparent in experiments conducted using highly expressed model antigens (e.g., ovalbumin). Second, clearance of apoptotic cells and debris might be expected to reduce the presence of alarmins or DAMPs. Third, tissue-resident macrophages are known to suppress their own activation in response to apoptotic cell phagocytosis<sup>84</sup>. This includes phagocytic pathways designed to avoid activation of cytosolic sensors such as stimulator of interferon genes (STING)<sup>151,152</sup>, as well as the secretion of factors that suppress the activation of neighboring cells<sup>153</sup>. One of these secreted factors, insulin-like growth factor-1, has already been shown to promote the regrowth of gliomas following CSF1R inhibition<sup>154</sup>. Any of these mechanisms, or a combination of them, could theoretically reduce the capacity of the CD103<sup>+</sup> cDC subset to transport tumor antigens to the draining lymph node and initiate a de novo CD8<sup>+</sup> T cell response<sup>149,150</sup>.

Alternatively, it has recently been described that embryonically-derived tissue-resident macrophages are present within tumors, and that these cells retain a distinct phenotype from their monocyte-derived macrophage counterparts<sup>31,32</sup>. A unique property of many tissue-resident macrophages is expression of CD169/Siglec-1<sup>155</sup>, which has been shown to selectively bind to CD8 $\alpha$ <sup>+</sup> cDCs and promote antigen transfer within secondary lymphoid organs<sup>156</sup>. Whether CD169<sup>+</sup> macrophages are present in tumors and transfer antigen to the equivalent CD103<sup>+</sup> cDC subset is unknown. This pathway also appears irrelevant for soluble or Fc receptor-mediated uptake of antigens by cDCs<sup>156</sup>, but could be involved in the transfer of cellular antigens, particularly during early tumor progression when tissue-resident macrophages might be expected to dominate the microenvironment. Interestingly, it has been demonstrated that tissue-resident CD169<sup>+</sup> macrophages in the spleen and lymph node capture extracellular vesicles<sup>157</sup>, a process that restricts entrance into the lymph node cortex and prevents their interaction with B cells<sup>157,158</sup>. In tumor models, the absence of CD169<sup>+</sup> macrophages increases production of immunoglobulin<sup>158</sup>, which subsequently drives the polarization of tumor macrophages via activating Fc $\gamma$  receptors to increase neoplastic progression, tumor growth, and resistance to chemotherapy<sup>101-103</sup>.

### Therapeutic targeting of TAMs

Given the importance of TAMs in regulating tumor immunity, there has been considerable interest in therapeutic strategies that target macrophages, which can be roughly divided into those that either deplete or alter TAM protumoral activities. As preclinical evidence largely supports combinatorial approaches being necessary to observe efficacy<sup>6</sup>, these strategies are

currently in evaluation either to augment tumor immunity during standard chemotherapy or radiation therapy, or in combination with T cell-directed immunotherapy (Table 1). Herein, we will discuss the potential strengths and weaknesses of these approaches, and suggest future directions for clinical trials.

### Targeting TAM recruitment and survival.

One strategy to deplete TAMs is to cut off their replenishment by circulating inflammatory monocytes. Circulating monocytes are highly dependent on CCL2–CCR2 signaling for their mobilization from the bone marrow and recruitment into inflammatory sites; thus, CCR2 inhibition keeps monocytes in the bone marrow, resulting in depleted pools of circulating cells and reduced numbers of TAMs in primary and metastatic sites<sup>159–164</sup>. In preclinical models, CCL2/CCR2 blockade can improve the efficacy of chemotherapy, radiation therapy, and immunotherapy<sup>61,159,160,165–167</sup>. Several CCR2 blockade combination clinical trials are therefore ongoing. One early study in pancreatic cancer showed a >40% increase in responsiveness to chemotherapy when CCR2 inhibitors were combined with the chemotherapy regimen, FOLFIRINOX<sup>159</sup>. Biomarker analysis in this study also showed that combination therapy was associated with increased T cell infiltration. Similar observations have been made in some of the preclinical models, facilitating further combinations with checkpoint immunotherapy. Clinical testing of this triple combination, i.e., CCR2 inhibition, chemotherapy, and checkpoint blockade, are now ongoing. Although CCR2 plays a dominant role in macrophage recruitment, important considerations for combined efficacy include rapid compensation by granulocytes and lack of efficacy in impacting resident TAMs populations<sup>31,168</sup>. It has also been observed that cessation of CCL2/CCR2 blockade leads to release of the monocytes previously trapped within the bone marrow, and this can exacerbate metastasis in a murine model of breast cancer<sup>169</sup>. These parameters will be critical to consider in the design of future clinical trials.

The CSF1–CSF1R axis has also been heavily investigated in preclinical models. In most tumors, inhibition of CSF1–CSF1R signaling leads to the apoptotic death of a significant portion of TAMs, the outlier being glioma models where compensatory activity by GM-CSF leads to TAM survival and repolarization<sup>10</sup>. Independent of the mechanism of action, in a significant array of animal models, CSF1R inhibition improves T cell responses in combination with radiation or chemotherapeutic agents<sup>61,107,170–173</sup>. Additionally, CSF1–CSF1R blockade improves the efficacy of the diversity of immunotherapeutic modalities, including CD40 agonists, PD-1, or CTLA-4 antagonists, and adoptive T cell therapy<sup>12,147,174–176</sup>. The sum of these studies has led to a number of clinical trials combining CSF-1/CSF-1R inhibitors with immune checkpoint blockade. In a promising study in pancreatic cancer patients, which do not traditionally respond to immunotherapy, it has been reported that some patient responses were observed with the combination of CSF-1R and PD-1 antagonists<sup>177</sup>, and these studies are now moving forward to a multi-arm Phase II clinical trial. Despite the breadth and consistency of these findings, it is perhaps not surprising that compensatory resistance pathways have already been defined that ultimately limit the durability of the response to CSF-1R inhibitors<sup>154,178,179</sup>. The other major barrier to translation may be that TAM depletion coincides with loss of tissue-resident populations important for maintaining homeostasis<sup>180</sup>. Although elevated liver enzymes appear to be a

byproduct of reduced clearance by Kupffer cells, and not evidence of liver toxicity, grade 3 adverse events may limit the utility of CSF-1R antagonists in combination studies<sup>181</sup>.

Other pathways involved in macrophage recruitment include the CXCL12/CXCR4 and angiopoietin-2/Tie2 axes. In glioma and breast models, radiation, chemotherapy, and vascular disruption have been shown to increase CXCL12 expression and promote CXCR4-dependent macrophage repopulation and treatment resistance<sup>133,182–184</sup>. Intriguingly, it appears that CXCL12 acts by preferentially recruiting Tie2<sup>+</sup> macrophages, a population that is strongly associated with the vasculature and is important for tumor angiogenesis<sup>185</sup>. Thus, depleting Tie2<sup>+</sup> macrophages improves vascular disruption<sup>184</sup>, neutralizing angiopoietin-2 improves responses to VEGFA blockade<sup>186</sup>, and inhibiting Tie2 blocks chemotherapy-induced Tie2<sup>+</sup> TAM recruitment in breast models and leads to decreased metastasis<sup>187,188</sup>. Though the impact of Tie2<sup>+</sup> TAMs on tumor immunity and the potential for immunotherapy combinations are unclear, it has been found that dual neutralization of angiopoietin-2 and VEGFA promotes T cell infiltration, and that efficacy is completely dependent upon CD8<sup>+</sup> T cells<sup>186</sup>. CXCR4 inhibition also renders pancreatic cancer models more responsive to checkpoint blockade<sup>189</sup>, although whether this is related to macrophages is unclear.

### Targeting TAM activation

An intrinsic downside to depleting TAMs is the loss of their latent immune stimulatory role as the primary phagocyte and professional antigen-presenting cell within tumors. Reprogramming or ‘repolarizing’ TAMs towards an anti-tumor phenotype could therefore prove a more efficacious—if potentially more toxic—approach to augmenting other forms of immunotherapy. One of the most productive approaches to date has been the use of an agonist CD40 antibody<sup>190</sup>, which shows combinatorial efficacy in pancreatic cancer with gemcitabine<sup>191</sup> and gemcitabine/nab-paclitaxel<sup>192</sup>. As CD40 is expressed by DCs, the relative contribution of TAM versus DC activation is unclear, but critically, enhanced responses to PD-1 and CTLA-4 antagonists have been observed<sup>193</sup>. Clinical trials combining a CD40 agonist with chemotherapy, immunotherapy, and angiogenic inhibitors are currently ongoing. Intriguingly, efficacy has also been described when combining CD40 agonists with various CSF-1R-targeted agents. This effect occurs in systems where the number of TAMs is not impacted by CSF-1R inhibition<sup>176,194</sup>, but also when TAM depletion is effective<sup>195</sup>. In either case, it appears that blocking CSF-1R sensitizes residual TAMs to reprogramming by anti-CD40 and promotes enhanced T cell-dependent immunity.

Epigenetic reprogramming of macrophages through inhibition of histone deacetylases (HDAC) can also elicit a T cell supportive role. Specifically, in mammary tumor models, a selective HDAC IIa inhibitor induces anti-tumor macrophage phenotypes that support T cell responses and increase responses to chemotherapy and immune checkpoint blockade<sup>196</sup>. Pan-HDAC inhibitors are already being tested with PD-1 antagonists, and it is possible that macrophage reprogramming could have a significant role in mediating therapeutic efficacy. An alternative approach to reprogramming, which has been evaluated extensively in preclinical models, involves targeting the major pathways that drive the immunosuppressive function of TAMs, including IL-4, IL-13, and immunoglobulins<sup>6</sup>. However, although clinical agents for these pathways exist, the interest in using them in solid malignancies to promote

immunity has been minimal. An exception to this has been the targeting of PI3K $\gamma$ , which is activated in TAMs downstream of multiple pathways, including the Fc $\gamma$  receptor. Activation of PI3K $\gamma$  signaling in macrophages has been shown to drive TAM immunosuppressive activities in models of lung, melanoma, and pancreatic cancer<sup>106,197–200</sup>. In animal models, pharmacological inhibition of PI3K $\gamma$  results in macrophage reprogramming and augmentation of T cell responses as a single agent<sup>105</sup>, and in combination with T cell checkpoint blockade<sup>106,198,200</sup>.

## Future directions

Given the myriad of roles for TAMs, therapeutically targeting one specific function of these cells may prove difficult. Success has been observed in multiple xenograft models by blocking CD47, a membrane bound protein that interacts with SIRP $\alpha$  on TAMs to inhibit phagocytosis<sup>201</sup>. However, it should be noted that SIRP $\alpha$  is also expressed on CD11b<sup>+</sup> DCs, and in syngeneic models, the ability of CD47 blockade to promote an immune response is dependent upon cytosolic sensing of tumor DNA by DCs<sup>202,203</sup>. Although this does not negate the approach, the degree to which efficacy is macrophage-dependent is unclear. Intriguingly, recent data have suggested that PD-L1/PD-1 signaling on TAMs impairs their phagocytic capacity and anti-tumor phenotype<sup>204,205</sup>, suggesting a second point of synergy for CD47/PD1 combinations. In addition, macrophages have been shown to uptake anti-PD-1 antibodies through their Fc $\gamma$  receptors, thereby limiting efficacy, in animal models<sup>206</sup>. The binding of antibodies to macrophage Fc receptors has been shown to regulate a number of therapeutic responses *in vivo*, and is a critical aspect of antibody drug design<sup>207</sup>. The importance of macrophages in regulating these responses also needs to be considered when designing clinical studies, especially when incorporating CSF-1R or CCR2 inhibitors that could limit therapeutic efficacy.

The sum of pre-clinical animal and correlative human studies suggest that targeting TAMs could significantly improve the efficacy of conventional and immunotherapeutics. However, in spite of the clinical interest and a few suggestive early trial outcomes<sup>159,177</sup>, the optimum therapeutic approach has yet to be identified. This may be partially due to a lack of data on key clinical parameters that may determine the success or failure of combinatorial therapeutic approaches in humans. For example, while several cancer types, such as ovarian, pancreas, and mesothelioma, have relatively high macrophage infiltration, it is unknown if these reflect patient populations that will see maximal benefit. Other questions include what type of approach (i.e. depletion or reprogramming) should be employed, and whether the best therapeutic modalities might be cancer type dependent. In addition, if TAM antagonists are being used to overcome resistance to immunotherapy, then more clinical data correlating macrophage infiltration or phenotype with patient outcomes is needed to guide patient selection. Finally, it will be critical to determine how exactly to employ these therapeutic combinations, including data driven considerations of dosing strategies and sequencing to minimize potential toxicities and/or maximize immune stimulatory properties. For example, anti-CD40 antibody demonstrated toxicity in mice when given prior to gemcitabine in a pancreatic tumor model<sup>208</sup>. The challenge will be to empirically design trials rather than base them upon historical doses, clinical practicality, or financial considerations. In spite of

these challenges, there remains significant potential to harness macrophage biology to improve outcomes for cancer patients.

## Acknowledgements

The laboratory of D.G.D. is supported by funding from National Cancer Institute, including P50CA196510, R01CA177670, R01CA203890, P30CA091842 Supplement-15S3, as well as The Mary Kay Foundation. The laboratory of B.R. is supported by funding from the National Institute of Health (R00CA185325), Florida Department of Health Bankhead-Coley Cancer Research Program (8BC02) and the Florida Breast Cancer Foundation. The authors thank members of their laboratories for helpful discussion.

## Glossary Terms:

### **Tumor microenvironment**

The tumor microenvironment (TME) is the cellular and acellular components in which malignant cells reside. These include surrounding blood vessels, immune cells, fibroblasts, extracellular matrix components, extracellular signaling molecules such as chemokines, cytokines, and growth factors, as well as metabolic regulators such as oxygen.

### **Tumor immune microenvironment**

The tumor immune microenvironment (TIME) is the components of the tumor microenvironment represented by leukocytes or their derived factors.

### **Desmoplasia**

Cancer associated desmoplasia is the growth and expansion of fibrous and/or connective tissue surrounding the malignant cells. Desmoplasia may occur around a growing neoplasm and consists of expansion of the non-malignant cellular components, such as activated fibroblasts beyond the norms of the homeostatic tissue levels.

## References

1. Zhang QW et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. *PloS one* 7, e50946, doi:10.1371/journal.pone.0050946 (2012). [PubMed: 23284651]
2. Komohara Y, Jinushi M & Takeya M Clinical significance of macrophage heterogeneity in human malignant tumors. *Cancer science* 105, 1–8, doi:10.1111/cas.12314 (2014). [PubMed: 24168081]
3. Gentles AJ et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat Med* 21, 938–945, doi:10.1038/nm.3909 (2015). [PubMed: 26193342]
4. Canli O et al. Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. *Cancer cell* 32, 869–883 e865, doi:10.1016/j.ccell.2017.11.004 (2017). [PubMed: 29232557]
5. Qian BZ & Pollard JW Macrophage diversity enhances tumor progression and metastasis. *Cell* 141, 39–51, doi:10.1016/j.cell.2010.03.014 (2010). [PubMed: 20371344]
6. Ruffell B & Coussens LM Macrophages and Therapeutic Resistance in Cancer. *Cancer Cell* 27, 462–472, doi:10.1016/j.ccell.2015.02.015 (2015). [PubMed: 25858805]
7. Coffelt SB & de Visser KE Immune-mediated mechanisms influencing the efficacy of anticancer therapies. *Trends in immunology* 36, 198–216, doi:10.1016/j.it.2015.02.006 (2015). [PubMed: 25857662]
8. Engblom C, Pfirschke C & Pittet MJ The role of myeloid cells in cancer therapies. *Nat Rev Cancer* 16, 447–462, doi:10.1038/nrc.2016.54 (2016). [PubMed: 27339708]
9. Noy R & Pollard JW Tumor-associated macrophages: from mechanisms to therapy. *Immunity* 41, 49–61, doi:10.1016/j.immuni.2014.06.010 (2014). [PubMed: 25035953]

10. Pyonteck SM et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. *Nat Med* 19, 1264–1272, doi:10.1038/nm.3337 (2013). [PubMed: 24056773]
11. Olson OC, Kim H, Quail DF, Foley EA & Joyce JA Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents. *Cell Rep* 19, 101–113, doi:10.1016/j.celrep.2017.03.038 (2017). [PubMed: 28380350]
12. Zhu Y et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. *Cancer Res* 74, 5057–5069, doi:10.1158/0008-5472.CAN-13-3723 (2014). [PubMed: 25082815]
13. Bonnardel J & Guillemins M Developmental control of macrophage function. *Curr Opin Immunol* 50, 64–74, doi:10.1016/j.coi.2017.12.001 (2018). [PubMed: 29247852]
14. Epelman S, Lavine KJ & Randolph GJ Origin and functions of tissue macrophages. *Immunity* 41, 21–35, doi:10.1016/j.immuni.2014.06.013 (2014). [PubMed: 25035951]
15. Lavin Y, Mortha A, Rahman A & Merad M Regulation of macrophage development and function in peripheral tissues. *Nat Rev Immunol* 15, 731–744, doi:10.1038/nri3920 (2015). [PubMed: 26603899]
16. Ginhoux F & Guillemins M Tissue-Resident Macrophage Ontogeny and Homeostasis. *Immunity* 44, 439–449, doi:10.1016/j.immuni.2016.02.024 (2016). [PubMed: 26982352]
17. Mantovani A, Sozzani S, Locati M, Allavena P & Sica A Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol* 23, 549–555 (2002). [PubMed: 12401408]
18. Murray PJ et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* 41, 14–20, doi:10.1016/j.immuni.2014.06.008 (2014). [PubMed: 25035950]
19. Mass E et al. Specification of tissue-resident macrophages during organogenesis. *Science* 353, doi:10.1126/science.aaf4238 (2016).
20. Hashimoto D et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity* 38, 792–804, doi:10.1016/j.immuni.2013.04.004 (2013). [PubMed: 23601688]
21. Schulz C et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science* 336, 86–90, doi:10.1126/science.1219179 (2012). [PubMed: 22442384]
22. Yona S et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* 38, 79–91, doi:10.1016/j.immuni.2012.12.001 (2013). [PubMed: 23273845]
23. Hoeffel G et al. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. *Immunity* 42, 665–678, doi:10.1016/j.immuni.2015.03.011 (2015). [PubMed: 25902481]
24. Ginhoux F et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. *Science* 330, 841–845, doi:10.1126/science.1194637 (2010). [PubMed: 20966214]
25. Calderon B et al. The pancreas anatomy conditions the origin and properties of resident macrophages. *J Exp Med* 212, 1497–1512, doi:10.1084/jem.20150496 (2015). [PubMed: 26347472]
26. Epelman S et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. *Immunity* 40, 91–104, doi:10.1016/j.immuni.2013.11.019 (2014). [PubMed: 24439267]
27. Gibbings SL et al. Transcriptome analysis highlights the conserved difference between embryonic and postnatal-derived alveolar macrophages. *Blood* 126, 1357–1366, doi:10.1182/blood-2015-01-624809 (2015). [PubMed: 26232173]
28. Loyher PL et al. Macrophages of distinct origins contribute to tumor development in the lung. *J Exp Med* 215, 2536–2553, doi:10.1084/jem.20180534 (2018). [PubMed: 30201786]
29. Lavin Y et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell* 159, 1312–1326, doi:10.1016/j.cell.2014.11.018 (2014). [PubMed: 25480296]
30. Gosselin D et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. *Cell* 159, 1327–1340, doi:10.1016/j.cell.2014.11.023 (2014). [PubMed: 25480297]

31. Zhu Y et al. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. *Immunity* 47, 323–338, doi:10.1016/j.immuni.2017.07.014 (2017). [PubMed: 28813661]
32. Bowman RL et al. Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. *Cell Rep* 17, 2445–2459, doi:10.1016/j.celrep.2016.10.052 (2016). [PubMed: 27840052]
33. Movahedi K et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. *Cancer Res* 70, 5728–5739, doi:10.1158/0008-5472.CAN-09-4672 (2010). [PubMed: 20570887]
34. Strachan DC et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. *Oncoimmunology* 2, e26968, doi:10.4161/onci.26968 (2013). [PubMed: 24498562]
35. Chen Z et al. Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. *Cancer Res* 77, 2266–2278, doi:10.1158/0008-5472.CAN-16-2310 (2017). [PubMed: 28235764]
36. Henze AT & Mazzone M The impact of hypoxia on tumor-associated macrophages. *J Clin Invest* 126, 3672–3679, doi:10.1172/JCI84427 (2016). [PubMed: 27482883]
37. Doedens AL et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. *Cancer Res* 70, 7465–7475, doi:10.1158/0008-5472.CAN-10-1439 (2010). [PubMed: 20841473]
38. Imtiyaz HZ et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. *J Clin Invest* 120, 2699–2714, doi:10.1172/JCI39506 (2010). [PubMed: 20644254]
39. Casazza A et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. *Cancer Cell* 24, 695–709, doi:10.1016/j.ccr.2013.11.007 (2013). [PubMed: 24332039]
40. Wallerius M et al. Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. *Cancer research* 76, 3166–3178, doi:10.1158/0008-5472.CAN-15-2596 (2016). [PubMed: 27197153]
41. Colegio OR et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature* 513, 559–563, doi:10.1038/nature13490 (2014). [PubMed: 25043024]
42. Geeraerts X, Bolli E, Fendt SM & Van Ginderachter JA Macrophage Metabolism As Therapeutic Target for Cancer, Atherosclerosis, and Obesity. *Front Immunol* 8, 289, doi:10.3389/fimmu.2017.00289 (2017). [PubMed: 28360914]
43. Freerman AJ et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. *J Biol Chem* 289, 7884–7896, doi:10.1074/jbc.M113.522037 (2014). [PubMed: 24492615]
44. Wang F et al. Glycolytic Stimulation Is Not a Requirement for M2 Macrophage Differentiation. *Cell Metab* 28, 463–475 e464, doi:10.1016/j.cmet.2018.08.012 (2018). [PubMed: 30184486]
45. Huang SC et al. Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation. *Immunity* 45, 817–830, doi:10.1016/j.immuni.2016.09.016 (2016). [PubMed: 27760338]
46. Wenes M et al. Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis. *Cell Metab* 24, 701–715, doi:10.1016/j.cmet.2016.09.008 (2016). [PubMed: 27773694]
47. Penny HL et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. *Oncoimmunology* 5, e1191731, doi:10.1080/2162402X.2016.1191731 (2016). [PubMed: 27622062]
48. Jones RS & Morris ME Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease. *Clin Pharmacol Ther* 100, 454–463, doi:10.1002/cpt.418 (2016). [PubMed: 27351344]
49. Bohn T et al. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. *Nat Immunol* 19, 1319–1329, doi:10.1038/s41590-018-0226-8 (2018). [PubMed: 30397348]



50. El-Kenawi A et al. Acidity promotes tumor progression by altering macrophage phenotype in prostate cancer. *bioRxiv*. doi:10.1101/478420 (2018).
51. Radu CG, Nijagal A, McLaughlin J, Wang L & Witte ON Differential proton sensitivity of related G protein-coupled receptors T cell death-associated gene 8 and G2A expressed in immune cells. *Proceedings of the National Academy of Sciences of the United States of America* 102, 1632–1637, doi:10.1073/pnas.0409415102 (2005). [PubMed: 15665078]
52. Kalluri R The biology and function of fibroblasts in cancer. *Nat Rev Cancer* 16, 582–598, doi:10.1038/nrc.2016.73 (2016). [PubMed: 27550820]
53. Chomarat P, Banchereau J, Davoust J & Palucka AK IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. *Nature immunology* 1, 510–514, doi:10.1038/82763 (2000). [PubMed: 11101873]
54. Wu MH et al. Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. *Clinical cancer research : an official journal of the American Association for Cancer Research* 17, 1306–1316, doi:10.1158/1078-0432.CCR-10-1824 (2011). [PubMed: 21385934]
55. Torres S et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 19, 6006–6019, doi:10.1158/1078-0432.CCR-13-1130 (2013). [PubMed: 24025712]
56. Mathew E et al. Mesenchymal Stem Cells Promote Pancreatic Tumor Growth by Inducing Alternative Polarization of Macrophages. *Neoplasia* 18, 142–151, doi:10.1016/j.neo.2016.01.005 (2016). [PubMed: 26992915]
57. Kim JH et al. The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myeloid cells in the colorectal cancer microenvironment. *Biochemical and biophysical research communications* 423, 60–66, doi:10.1016/j.bbrc.2012.05.081 (2012). [PubMed: 22634002]
58. Mace TA et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. *Cancer research* 73, 3007–3018, doi:10.1158/0008-5472.CAN-12-4601 (2013). [PubMed: 23514705]
59. Kumar V et al. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. *Immunity* 44, 303–315, doi:10.1016/j.immuni.2016.01.014 (2016). [PubMed: 26885857]
60. Wang Q et al. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2 $\alpha$ . *Nat Commun* 9, 559, doi:10.1038/s41467-018-03050-0 (2018). [PubMed: 29422647]
61. Mitchem JB et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. *Cancer Res* 73, 1128–1141, doi:10.1158/0008-5472.CAN-12-2731 (2013). [PubMed: 23221383]
62. Song L et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. *J Clin Invest* 119, 1524–1536, doi:37869 [pii] 10.1172/JCI37869 (2009). [PubMed: 19411762]
63. Costa A et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. *Cancer Cell* 33, 463–479 e410, doi:10.1016/j.ccell.2018.01.011 (2018). [PubMed: 29455927]
64. Givel AM et al. miR200-regulated CXCL12 $\beta$  promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. *Nat Commun* 9, 1056, doi:10.1038/s41467-018-03348-z (2018). [PubMed: 29535360]
65. Zhou W et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. *Nat Cell Biol* 17, 170–182, doi:10.1038/ncb3090 (2015). [PubMed: 25580734]
66. Pickup MW, Mouw JK & Weaver VM The extracellular matrix modulates the hallmarks of cancer. *EMBO Rep* 15, 1243–1253, doi:10.15252/embr.201439246 (2014). [PubMed: 25381661]
67. Stahl M et al. Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. *PLoS One* 8, e81382, doi:10.1371/journal.pone.0081382 (2013). [PubMed: 24278429]

68. Wesley RB 2nd, Meng X, Godin D & Galis ZS Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. *Arterioscler Thromb Vasc Biol* 18, 432–440 (1998). [PubMed: 9514412]
69. Meyaard L The inhibitory collagen receptor LAIR-1 (CD305). *J Leukocyte Biol* 83, 799–803, doi:10.1189/jlb.0907609 (2008). [PubMed: 18063695]
70. McWhorter FY, Davis CT & Liu WF Physical and mechanical regulation of macrophage phenotype and function. *Cell Mol Life Sci* 72, 1303–1316, doi:10.1007/s00018-014-1796-8 (2015). [PubMed: 25504084]
71. Van Goethem E, Poincloux R, Gauffre F, Maridonneau-Parini I & Le Cabec V Matrix Architecture Dictates Three-Dimensional Migration Modes of Human Macrophages: Differential Involvement of Proteases and Podosome-Like Structures. *Journal of immunology* 184, 1049–1061, doi:10.4049/jimmunol.0902223 (2010).
72. McWhorter FY, Davis CT & Liu WF Physical and mechanical regulation of macrophage phenotype and function. *Cell Mol Life Sci* 72, 1303–1316, doi:10.1007/s00018-014-1796-8 (2015). [PubMed: 25504084]
73. Sulzmaier FJ, Jean C & Schlaepfer DD FAK in cancer: mechanistic findings and clinical applications. *Nat Rev Cancer* 14, 598–610, doi:10.1038/nrc3792 (2014). [PubMed: 25098269]
74. Jiang H et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. *Nat Med* 22, 851–860, doi:10.1038/nm.4123 (2016). [PubMed: 27376576]
75. Laklai H et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. *Nat Med*, doi:10.1038/nm.4082 (2016).
76. Sorokin L The impact of the extracellular matrix on inflammation. *Nat Rev Immunol* 10, 712–723, doi:10.1038/nri2852 (2010). [PubMed: 20865019]
77. Tang M et al. Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling. *Cell Rep* 13, 2851–2864, doi:10.1016/j.celrep.2015.11.053 (2015). [PubMed: 26711349]
78. Kim S et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. *Nature* 457, 102–106, doi:10.1038/nature07623 (2009). [PubMed: 19122641]
79. Kobayashi N et al. Hyaluronan Deficiency in Tumor Stroma Impairs Macrophage Trafficking and Tumor Neovascularization. *Cancer research* 70, 7073–7083, doi:10.1158/0008-5472.CAN-09-4687 (2010). [PubMed: 20823158]
80. Jameson JM, Cauvi G, Sharp LL, Witherden DA & Havran WL Gammadelta T cell-induced hyaluronan production by epithelial cells regulates inflammation. *The Journal of experimental medicine* 201, 1269–1279, doi:10.1084/jem.20042057 (2005). [PubMed: 15837812]
81. Lee-Sayer SS et al. The where, when, how, and why of hyaluronan binding by immune cells. *Front Immunol* 6, 150, doi:10.3389/fimmu.2015.00150 (2015). [PubMed: 25926830]
82. Kroemer G, Galluzzi L, Kepp O & Zitvogel L Immunogenic cell death in cancer therapy. *Annu Rev Immunol* 31, 51–72, doi:10.1146/annurev-immunol-032712-100008 (2013). [PubMed: 23157435]
83. Huber R et al. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. *Sci Rep* 6, 29914, doi:10.1038/srep29914 (2016). [PubMed: 27426915]
84. Roberts AW et al. Tissue-Resident Macrophages Are Locally Programmed for Silent Clearance of Apoptotic Cells. *Immunity* 47, 913–927 e916, doi:10.1016/j.immuni.2017.10.006 (2017). [PubMed: 29150239]
85. Graham DK, DeRyckere D, Davies KD & Earp HS The TAM family: phosphatidyserine sensing receptor tyrosine kinases gone awry in cancer. *Nat Rev Cancer* 14, 769–785, doi:10.1038/nrc3847 (2014). [PubMed: 25568918]
86. Cook RS et al. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. *J Clin Invest* 123, 3231–3242, doi:10.1172/JCI67655 (2013). [PubMed: 23867499]
87. Crittenden MR et al. Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. *Oncotarget* 7, 78653–78666, doi:10.18632/oncotarget.11823 (2016). [PubMed: 27602953]

88. Ubil E et al. Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. *J Clin Invest* 128, 2356–2369, doi:10.1172/JCI97354 (2018). [PubMed: 29708510]
89. Ruffell B, Affara NI & Coussens LM Differential macrophage programming in the tumor microenvironment. *Trends in immunology* 33, 119–126, doi:10.1016/j.it.2011.12.001 (2012). [PubMed: 22277903]
90. Biswas SK & Mantovani A Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nat Immunol* 11, 889–896, doi:ni.1937 [pii] 10.1038/ni.1937 (2010). [PubMed: 20856220]
91. Marigo I et al. T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. *Cancer cell* 30, 377–390, doi:10.1016/j.ccell.2016.08.004 (2016). [PubMed: 27622331]
92. Klug F et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. *Cancer Cell* 24, 589–602, doi:10.1016/j.ccr.2013.09.014 (2013). [PubMed: 24209604]
93. DeNardo DG et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer Cell* 16, 91–102, doi:10.1016/j.ccr.2009.06.018 (2009). [PubMed: 19647220]
94. Shiao SL et al. TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. *Cancer Immunol Res* 3, 518–525, doi:10.1158/2326-6066.CIR-14-0232 (2015). [PubMed: 25716473]
95. Kryczek I et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. *J Exp Med* 203, 871–881, doi:10.1084/jem.20050930 (2006). [PubMed: 16606666]
96. Kryczek I et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. *Cancer Res* 67, 8900–8905, doi:10.1158/0008-5472.CAN-07-1866 (2007). [PubMed: 17875732]
97. Coffelt SB et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. *Nature*, doi:10.1038/nature14282 (2015).
98. Shahrara S, Pickens SR, Dorfleutner A & Pope RM IL-17 induces monocyte migration in rheumatoid arthritis. *J Immunol* 182, 3884–3891, doi:10.4049/jimmunol.0802246 (2009). [PubMed: 19265168]
99. Jovanovic DV et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. *J Immunol* 160, 3513–3521 (1998). [PubMed: 9531313]
100. Greenlee-Wacker MC Clearance of apoptotic neutrophils and resolution of inflammation. *Immunol Rev* 273, 357–370, doi:10.1111/imr.12453 (2016). [PubMed: 27558346]
101. Andreu P et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. *Cancer Cell* 17, 121–134, doi:10.1016/j.ccr.2009.12.019 (2010). [PubMed: 20138013]
102. de Visser KE, Korets LV & Coussens LM De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. *Cancer Cell* 7, 411–423, doi:10.1016/j.ccr.2005.04.014 (2005). [PubMed: 15894262]
103. Affara NI et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. *Cancer Cell* 25, 809–821, doi:10.1016/j.ccr.2014.04.026 (2014). [PubMed: 24909985]
104. Gunderson AJ et al. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. *Cancer Discov* 6, 270–285, doi:10.1158/2159-8290.CD-15-0827 (2016). [PubMed: 26715645]
105. Kaneda MM et al. Macrophage PI3Kgamma Drives Pancreatic Ductal Adenocarcinoma Progression. *Cancer Discov* 6, 870–885, doi:10.1158/2159-8290.CD-15-1346 (2016). [PubMed: 27179037]
106. Kaneda MM et al. PI3Kgamma is a molecular switch that controls immune suppression. *Nature* 539, 437–442, doi:10.1038/nature19834 (2016). [PubMed: 27642729]

107. DeNardo DG et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. *Cancer Discov* 1, 54–67, doi:10.1158/2159-8274.CD-10-0028 (2011). [PubMed: 22039576]
108. Ruffell B et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. *Cancer Cell* 26, 623–637 (2014). [PubMed: 25446896]
109. Kusmartsev S & Gabrilovich DI STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. *J Immunol* 174, 4880–4891 (2005). [PubMed: 15814715]
110. Gabrilovich DI & Nagaraj S Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol* 9, 162–174, doi:10.1038/nri2506 (2009). [PubMed: 19197294]
111. Geiger R et al. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. *Cell* 167, 829–842 e813, doi:10.1016/j.cell.2016.09.031 (2016). [PubMed: 27745970]
112. Marigo I et al. T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. *Cancer Cell* 30, 377–390, doi:10.1016/j.ccell.2016.08.004 (2016). [PubMed: 27622331]
113. Rodriguez PC et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. *Cancer Res* 64, 5839–5849, doi:10.1158/0008-5472.CAN-04-0465 (2004). [PubMed: 15313928]
114. Chang CI, Liao JC & Kuo L Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. *Cancer Res* 61, 1100–1106 (2001). [PubMed: 11221839]
115. Bronte V & Zanovello P Regulation of immune responses by L-arginine metabolism. *Nat Rev Immunol* 5, 641–654, doi:10.1038/nri1668 (2005). [PubMed: 16056256]
116. Lu T et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. *J Clin Invest* 121, 4015–4029, doi:10.1172/JCI45862 (2011). [PubMed: 21911941]
117. Lu T & Gabrilovich DI Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. *Clin Cancer Res* 18, 4877–4882, doi:10.1158/1078-0432.CCR-11-2939 (2012). [PubMed: 22718858]
118. Nagaraj S et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. *Nat Med* 13, 828–835, doi:10.1038/nm1609 (2007). [PubMed: 17603493]
119. Zea AH et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. *Cancer Res* 65, 3044–3048, doi:10.1158/0008-5472.CAN-04-4505 (2005). [PubMed: 15833831]
120. Munder M et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. *Blood* 105, 2549–2556, doi:10.1182/blood-2004-07-2521 (2005). [PubMed: 15546957]
121. Lin H et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. *J Clin Invest* 128, 805–815, doi:10.1172/JCI96113 (2018). [PubMed: 29337305]
122. Kuang DM et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. *J Exp Med* 206, 1327–1337, doi:10.1084/jem.20082173 (2009). [PubMed: 19451266]
123. Tang H et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. *J Clin Invest* 128, 580–588, doi:10.1172/JCI96061 (2018). [PubMed: 29337303]
124. Ceeraz S, Nowak EC & Noelle RJ B7 family checkpoint regulators in immune regulation and disease. *Trends in immunology* 34, 556–563, doi:10.1016/j.it.2013.07.003 (2013). [PubMed: 23954143]
125. Li J et al. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8(+) T Cells. *Immunity*, doi:10.1016/j.immuni.2018.03.018 (2018).
126. Kreymborg K et al. Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. *Cancer Immunol Res* 3, 849–854, doi:10.1158/2326-6066.CIR-15-0100 (2015). [PubMed: 26122284]

127. Rahbar R et al. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. *Cancer Immunol Res* 3, 184–195, doi:10.1158/2326-6066.CIR-14-0113 (2015). [PubMed: 25527357]
128. Smith LK et al. Interleukin-10 Directly Inhibits CD8(+) T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. *Immunity* 48, 299–312 e295, doi:10.1016/j.immuni.2018.01.006 (2018). [PubMed: 29396160]
129. Demotte N et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. *Immunity* 28, 414–424, doi:10.1016/j.immuni.2008.01.011 (2008). [PubMed: 18342010]
130. Henderson NC et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. *Am J Pathol* 172, 288–298, doi:10.2353/ajpath.2008.070726 (2008). [PubMed: 18202187]
131. Schuette V et al. Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-regulation of CTLA-4. *Proceedings of the National Academy of Sciences of the United States of America* 113, 10649–10654, doi:10.1073/pnas.1605885113 (2016). [PubMed: 27601670]
132. Stockmann C et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. *Nature* 456, 814–818, doi:10.1038/nature07445 (2008). [PubMed: 18997773]
133. Hughes R et al. Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. *Cancer Res* 75, 3479–3491, doi:10.1158/0008-5472.CAN-14-3587 (2015). [PubMed: 26269531]
134. Harney AS et al. Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA. *Cancer Discov* 5, 932–943, doi:10.1158/2159-8290.CD-15-0012 (2015). [PubMed: 26269515]
135. Sato E, Simpson KL, Grisham MB, Koyama S & Robbins RA Effects of reactive oxygen and nitrogen metabolites on RANTES- and IL-5-induced eosinophil chemotactic activity in vitro. *Am J Pathol* 155, 591–598, doi:10.1016/S0002-9440(10)65154-1 (1999). [PubMed: 10433951]
136. Sato E, Simpson KL, Grisham MB, Koyama S & Robbins RA Effects of reactive oxygen and nitrogen metabolites on MCP-1-induced monocyte chemotactic activity in vitro. *Am J Physiol* 277, L543–549 (1999). [PubMed: 10484461]
137. Molon B et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *J Exp Med* 208, 1949–1962, doi:10.1084/jem.20101956 (2011). [PubMed: 21930770]
138. Franciszkiwicz K, Boissonnas A, Boutet M, Combadiere C & Mami-Chouaib F Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. *Cancer Res* 72, 6325–6332, doi:10.1158/0008-5472.CAN-12-2027 (2012). [PubMed: 23222302]
139. Nielsen SR et al. Macrophage-secreted granulins supports pancreatic cancer metastasis by inducing liver fibrosis. *Nat Cell Biol* 18, 549–560, doi:10.1038/ncb3340 (2016). [PubMed: 27088855]
140. Quaranta V et al. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. *Cancer Res* 78, 4253–4269, doi:10.1158/0008-5472.CAN-17-3876 (2018). [PubMed: 29789416]
141. Tauriello DVF et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature* 554, 538–543, doi:10.1038/nature25492 (2018). [PubMed: 29443964]
142. Mariathasan S et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* 554, 544–548, doi:10.1038/nature25501 (2018). [PubMed: 29443960]
143. Kessenbrock K, Plaks V & Werb Z Matrix metalloproteinases: regulators of the tumor microenvironment. *Cell* 141, 52–67, doi:10.1016/j.cell.2010.03.015 (2010). [PubMed: 20371345]
144. Kelly A et al. Human monocytes and macrophages regulate immune tolerance via integrin alphaVbeta8-mediated TGFbeta activation. *J Exp Med* 215, 2725–2736, doi:10.1084/jem.20171491 (2018). [PubMed: 30355614]
145. de Mingo Pulido A et al. TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. *Cancer Cell* 33, 60–74 e66, doi:10.1016/j.ccell.2017.11.019 (2018). [PubMed: 29316433]

146. Broz ML et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. *Cancer Cell* 26, 638–652, doi:10.1016/j.ccell.2014.09.007 (2014). [PubMed: 25446897]
147. Peranzoni E et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. *Proceedings of the National Academy of Sciences of the United States of America* 115, E4041–E4050, doi:10.1073/pnas.1720948115 (2018). [PubMed: 29632196]
148. Curiel TJ et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* 10, 942–949, doi:10.1038/nm1093 (2004). [PubMed: 15322536]
149. Salmon H et al. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. *Immunity* 44, 924–938, doi:10.1016/j.immuni.2016.03.012 (2016). [PubMed: 27096321]
150. Roberts EW et al. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. *Cancer Cell* 30, 324–336, doi:10.1016/j.ccell.2016.06.003 (2016). [PubMed: 27424807]
151. Cunha LD et al. LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance. *Cell* 175, 429–441 e416, doi:10.1016/j.cell.2018.08.061 (2018). [PubMed: 30245008]
152. Ahn J, Xia T, Rabasa Capote A, Betancourt D & Barber GN Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells. *Cancer Cell* 33, 862–873 e865, doi:10.1016/j.ccell.2018.03.027 (2018). [PubMed: 29706455]
153. Han CZ et al. Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation. *Nature* 539, 570–574, doi:10.1038/nature20141 (2016). [PubMed: 27820945]
154. Quail DF et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. *Science* 352, aad3018, doi:10.1126/science.aad3018 (2016). [PubMed: 27199435]
155. Gupta P et al. Tissue-Resident CD169(+) Macrophages Form a Crucial Front Line against Plasmodium Infection. *Cell Rep* 16, 1749–1761, doi:10.1016/j.celrep.2016.07.010 (2016). [PubMed: 27477286]
156. van Dinther D et al. Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8(+) T Cell Cross-Priming. *Cell Rep* 22, 1484–1495, doi:10.1016/j.celrep.2018.01.021 (2018). [PubMed: 29425504]
157. Saunderson SC, Dunn AC, Crocker PR & McLellan AD CD169 mediates the capture of exosomes in spleen and lymph node. *Blood* 123, 208–216, doi:10.1182/blood-2013-03-489732 (2014). [PubMed: 24255917]
158. Pucci F et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. *Science* 352, 242–246, doi:10.1126/science.aaf1328 (2016). [PubMed: 26989197]
159. Nywening TM et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. *Lancet Oncol*, doi:10.1016/S1470-2045(16)00078-4 (2016).
160. Sanford DE et al. Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: a Role for Targeting the CCL2/CCR2 Axis. *Clin Cancer Res*, doi:10.1158/1078-0432.CCR-13-0525 (2013).
161. Zhao L et al. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. *Hepatology* 57, 829–839, doi:10.1002/hep.26094 (2013). [PubMed: 23081697]
162. Qian BZ et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. *Nature* 475, 222–225, doi:10.1038/nature10138 (2011). [PubMed: 21654748]
163. Lim SY, Yuzhalin AE, Gordon-Weeks AN & Muschel RJ Targeting the CCL2-CCR2 signaling axis in cancer metastasis. *Oncotarget* 7, 28697–28710, doi:10.18632/oncotarget.7376 (2016). [PubMed: 26885690]
164. Zhang J, Patel L & Pienta KJ CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. *Cytokine Growth Factor Rev* 21, 41–48, doi:S1359-6101(09)00116-6 [pii] 10.1016/j.cytogfr.2009.11.009 (2010). [PubMed: 20005149]

165. Connolly KA et al. Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes. *Oncotarget* 7, 86522–86535, doi:10.18632/oncotarget.13287 (2016). [PubMed: 27852031]
166. Kalbasi A et al. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. *Clin Cancer Res* 23, 137–148, doi:10.1158/1078-0432.CCR-16-0870 (2017). [PubMed: 27354473]
167. Fridlender ZG et al. CCL2 blockade augments cancer immunotherapy. *Cancer research* 70, 109–118, doi:10.1158/0008-5472.CAN-09-2326 (2010). [PubMed: 20028856]
168. Nywening TM et al. Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. *Gut*, doi:10.1136/gutjnl-2017-313738 (2017).
169. Bonapace L et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. *Nature* 515, 130–133, doi:10.1038/nature13862 (2014). [PubMed: 25337873]
170. Ruffell B et al. Macrophage IL10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL12 Expression in Intratumoral Dendritic Cells. *Cancer Cell* 26, 623–637 (2014). [PubMed: 25446896]
171. Xu J et al. Abrogating the protumorigenic influences of tumor-infiltrating myeloid cells by CSF1R signaling blockade improves the efficacy of radiotherapy in prostate cancer. *Cancer Res*, doi:10.1158/0008-5472.CAN-12-3981 (2013).
172. Seifert L et al. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. *Gastroenterology* 150, 1659–1672 e1655, doi:10.1053/j.gastro.2016.02.070 (2016). [PubMed: 26946344]
173. Wang Q et al. Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. *Leukemia* 32, 176–183, doi:10.1038/leu.2017.193 (2018). [PubMed: 28626216]
174. Neubert NJ et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. *Science translational medicine* 10, doi:10.1126/scitranslmed.aan3311 (2018).
175. Mok S et al. Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. *Cancer Res*, doi:10.1158/0008-5472.CAN-13-1816 (2013).
176. Wiehagen KR et al. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity. *Cancer Immunol Res* 5, 1109–1121, doi:10.1158/2326-6066.CIR-17-0258 (2017). [PubMed: 29097420]
177. Wainberg ZA et al. First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti-CSF-1 Receptor (cabiralizumab) Plus Anti-PD-1 (nivolumab), in Patients With Advanced Solid Tumors. SITC-Meeting Abstract, O42 (2017).
178. Kumar V et al. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. *Cancer Cell* 32, 654–668 e655, doi:10.1016/j.ccell.2017.10.005 (2017). [PubMed: 29136508]
179. Nywening T et al. Targeting tumor associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. *Gut In-Press* (2017).
180. Ries CH et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. *Cancer cell* 25, 846–859, doi:10.1016/j.ccr.2014.05.016 (2014). [PubMed: 24898549]
181. Cannarile MA et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. *J Immunother Cancer* 5, 53, doi:10.1186/s40425-017-0257-y (2017). [PubMed: 28716061]
182. Sanchez-Martin L et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. *Blood* 117, 88–97, doi:10.1182/blood-2009-12-258186 (2011). [PubMed: 20930067]
183. Wang SC, Yu CF, Hong JH, Tsai CS & Chiang CS Radiation therapy-induced tumor invasiveness is associated with SDF-1-regulated macrophage mobilization and vasculogenesis. *PLoS One* 8, e69182, doi:10.1371/journal.pone.0069182 (2013). [PubMed: 23940516]
184. Welford AF et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. *J Clin Invest* 121, 1969–1973, doi:10.1172/JCI44562 (2011). [PubMed: 21490397]


185. Mazzei R et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. *Cancer Cell* 19, 512–526, doi:10.1016/j.ccr.2011.02.005 (2011). [PubMed: 21481792]
186. Schmittnaegel M et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. *Sci Transl Med* 9, doi:10.1126/scitranslmed.aak9670 (2017).
187. Harney AS et al. The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2(Hi) Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors. *Mol Cancer Ther* 16, 2486–2501, doi:10.1158/1535-7163.MCT-17-0241 (2017). [PubMed: 28838996]
188. Karagiannis GS et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. *Science translational medicine* 9, doi:10.1126/scitranslmed.aan0026 (2017).
189. Feig C et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc Natl Acad Sci U S A* 110, 20212–20217, doi:10.1073/pnas.1320318110 (2013). [PubMed: 24277834]
190. Vonderheide RH The Immune Revolution: A Case for Priming, Not Checkpoint. *Cancer Cell* 33, 563–569, doi:10.1016/j.ccell.2018.03.008 (2018). [PubMed: 29634944]
191. Beatty GL et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. *Science* 331, 1612–1616, doi:10.1126/science.1198443 (2011). [PubMed: 21436454]
192. Byrne KT & Vonderheide RH CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. *Cell Rep* 15, 2719–2732, doi:10.1016/j.celrep.2016.05.058 (2016). [PubMed: 27292635]
193. Winograd R et al. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. *Cancer Immunol Res* 3, 399–411, doi:10.1158/2326-6066.CIR-14-0215 (2015). [PubMed: 25678581]
194. Perry CJ et al. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. *The Journal of experimental medicine* 215, 877–893, doi:10.1084/jem.20171435 (2018). [PubMed: 29436395]
195. Hoves S et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. *J Exp Med* 215, 859–876, doi:10.1084/jem.20171440 (2018). [PubMed: 29436396]
196. Guerriero JL et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. *Nature* 543, 428–432, doi:10.1038/nature21409 (2017). [PubMed: 28273064]
197. Schmid MC et al. PI3-kinase gamma promotes Rap1a-mediated activation of myeloid cell integrin alpha4beta1, leading to tumor inflammation and growth. *PLoS One* 8, e60226, doi:10.1371/journal.pone.0060226 (2013). [PubMed: 23565202]
198. Sai J et al. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. *Clin Cancer Res* 23, 3371–3384, doi:10.1158/1078-0432.CCR-16-2142 (2017). [PubMed: 28003307]
199. Foubert P, Kaneda MM & Varner JA PI3Kgamma Activates Integrin alpha4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression. *Cancer Immunol Res* 5, 957–968, doi:10.1158/2326-6066.CIR-17-0143 (2017). [PubMed: 28963139]
200. De Henau O et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. *Nature* 539, 443–447, doi:10.1038/nature20554 (2016). [PubMed: 27828943]
201. Willingham SB et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. *Proc Natl Acad Sci U S A* 109, 6662–6667, doi:10.1073/pnas.1121623109 (2012). [PubMed: 22451913]
202. Liu X et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. *Nature medicine* 21, 1209–1215, doi:10.1038/nm.3931 (2015).
203. Xu MM et al. Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein alpha Signaling. *Immunity* 47, 363–373 e365, doi:10.1016/j.immuni.2017.07.016 (2017). [PubMed: 28801234]



204. Gordon SR et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. *Nature* 545, 495–499, doi:10.1038/nature22396 (2017). [PubMed: 28514441]
205. Hartley GP, Chow L, Ammons DT, Wheat WH & Dow SW Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation. *Cancer Immunol Res* 6, 1260–1273, doi:10.1158/2326-6066.CIR-17-0537 (2018). [PubMed: 30012633]
206. Arlauckas SP et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. *Sci Transl Med* 9, doi:10.1126/scitranslmed.aal3604 (2017).
207. DiLillo DJ & Ravetch JV Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions. *Cancer Immunol Res* 3, 704–713, doi:10.1158/2326-6066.CIR-15-0120 (2015). [PubMed: 26138698]
208. Byrne KT, Leisenring NH, Bajor DL & Vonderheide RH CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. *J Immunol* 197, 179–187, doi:10.4049/jimmunol.1600146 (2016). [PubMed: 27217585]
209. Kitamura T, Qian BZ & Pollard JW Immune cell promotion of metastasis. *Nat Rev Immunol* 15, 73–86, doi:10.1038/nri3789 (2015). [PubMed: 25614318]
210. Yang M, McKay D, Pollard JW & Lewis CE Diverse Functions of Macrophages in Different Tumor Microenvironments. *Cancer Res* 78, 5492–5503, doi:10.1158/0008-5472.CAN-18-1367 (2018). [PubMed: 30206177]


**Box 1.****Tissue localization and macrophage heterogeneity.**

Most of the drivers of macrophage phenotype occur within distinct and heterogeneous microscopic areas, or niches. As reviewed elsewhere<sup>209,210</sup>, these niches exist in both primary tumors and disseminated sites, and can include areas defined by their relative proximity to cancer cell invasive fronts, tumor cell nests, fibrotic stroma, functional vasculature, or even the presence of tertiary lymphoid structures. These parameters lead to the classification of distinct macrophage populations (e.g. perivascular or hypoxic macrophages) that are better defined by their functionality within these niches than their expression of surface markers or activation state. As a consequence, it is likely that macrophages within these unique niches differentially regulate T cell function. For example, perivascular macrophages are expected to control vascular structure and T cell infiltration into the tumor parenchyma<sup>186</sup>, while hypoxic macrophages might have a more specialized role in governing T cell infiltration into tumor beds<sup>39</sup>. Additionally, these niches may be shaped by cancer therapy, for example, by immunotherapy increasing the frequency of tertiary lymphoid structures, or by vascular directed-therapy reshaping perivascular and hypoxic niches. Certainly multiple cytotoxic and targeted therapies are known to alter the phenotype of tumor macrophages as a whole<sup>7</sup>. Thus, while there are consistent drivers of macrophage function, the cumulative impact of these is highly dependent upon the microenvironmental niche occupied by the cells within the malignant tissue, in addition to the macroenvironment of the tumor and tissue type of residence.



**Figure 1. Macrophage origin and polarization state.**

Tissue macrophages are derived from embryonic or adult progenitor cells under homeostatic conditions, with the relative contribution of these populations varying by tissue. Monocyte-derived cells also contribute to the macrophage population in some tissues, but are mostly associated with a response to inflammatory conditions, including cancer. The combination of their developmental origin and tissue of residence is thought to fine-tune their eventual response to polarizing stimuli.



**Figure 2. Direct and indirect regulation of tumor immunity by TAMs.**

A) TAMs can directly inhibit T cell responses through three distinct mechanisms. These include checkpoint engagement via expression of molecules such as PD-L1, production of inhibitory cytokines such as IL-10, and through their metabolic activities, including depletion of metabolites and production of reactive oxygen species (ROS). B) TAMs also inhibit T cell responses indirectly by controlling the immune microenvironment. This includes recruitment of immunosuppressive populations (e.g.  $T_{regs}$ ) or by inhibiting stimulatory populations (e.g. cDCs). TAMs also blunt T cell recruitment via regulation of


vascular structure, and through their ability to exclude T cells from intratumoral regions via regulation of the extracellular matrix (ECM) and the chemokine milieu.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 3. Cell type versus integrated views on drivers of TAM phenotype.**

A) TAM phenotype is driven by a combination of the tumor microenvironment (TME) and the tumor immune microenvironment (TIME). On the left, responses by adaptive and innate immune cells provide cytokines and other factors that regulate macrophage bioactivities. On the right, properties of the tumor microenvironment like hypoxia, fibrosis and cellular stress also tailor the phenotype of TAMs. B) Both immune and non-immune related factors integrate to drive functional or dysfunctional anti-tumor immunity. On the left, the presence of a robust adaptive immune response is concomitant with limited tissue pathology and

macrophages programmed to drive inflammation. On the right, tumor hypoxia and fibrosis are integrated with high CAF and immunosuppressive cell infiltration, and macrophages are programmed to drive immune suppression and tissue remodelling, leading to CTL exclusion and/or suppression.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 1**

## Immuno-oncology Combinations

TAM Targeted Agent	Immune Modulator	Clinical Trial(s)
CSF1/CSF1R agonists	PD-1 or PD-L1 antagonists	NCT02554812* NCT02452424 <sup>-n</sup> NCT02777710* NCT02880371* NCT03238027* NCT02526017 <sup>-n</sup> NCT02829723* NCT02323191* NCT03158272* NCT02713529 <sup>-n</sup>
CCR2/5-antagonists	PD-1 or PD-L1 antagonists	NCT02723006 <sup>-n</sup> NCT03184870*
CXCR4 antagonist	PD-L1 antagonists	NCT02737072 <sup>-n</sup> NCT03193190* NCT02907099* NCT03154827* NCT03337698* NCT02823405*
Ang2/Tie2	PD-1 antagonists	NCT03239145*
CD40-agonists	PD-1 or PD-L1 antagonists	NCT03123783* NCT02304393*
CD47 (SIRP $\alpha$ -Fc)	PD-1 or PD-L1 antagonists	NCT03530683* NCT02890368* NCT03013218*
PI3K $\gamma$ / $\delta$ inhibitors	PD-1 or PD-L1 antagonists	NCT03471351* NCT02637531*
<b>Multimodality Immuno-oncology Combinations</b>		
TAM Targeted Agent	Immune Modulator	Clinical Trial(s)
CSF1R	Chemotherapy + PD1/PDL1	NCT02323191* NCT03336216*
CSF1R	PD-1 antagonist + SBRT	NCT03431948*
CSF1R	PD-1 antagonist + CD40 agonist	NCT03502330*
CSF1R	GVAX + PD-1 antagonist	NCT03153410*
CCR2/5 inhibition	Chemotherapy + PD-1 antagonist	NCT03184870* NCT03496662*

\* trial currently open and active

<sup>-n</sup> trial closed